Table 5.
Comparison of detailed lipid profile changes in the TAF group compared to the inactive CHB and non-HBV-infected control groups at baseline and 48 weeks
| Lipid level | At baseline |
At 48 weeks |
At baseline |
At 48 weeks |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TAF (n=56) | Inactive CHB (n=56) | P-value | TAF (n=56) | Inactive CHB (n=56) | P-value | TAF (n=45) | Non-HBV-infected control (n=180) | P-value | TAF (n=45) | Non-HBV-infected control (n=180) | P-value | |
| TC (mg/dL) | 168.0±33.7 | 163.6±25.0 | 0.323 | 169.8±33.9 | 168.1±32.6 | 0.734 | 169.8±28.5 | 167.8±35.0 | 0.689 | 176.6±31.3 | 178.5±36.0 | 0.729 |
| LDL-C (mg/dL) | 108.4±30.1 | 106.6±24.3 | 0.683 | 111.1±31.0 | 111.0±30.3 | 0.997 | 111.1±28.4 | 107.6±27.7 | 0.458 | 117.4±30.3 | 116.8±32.4 | 0.902 |
| HDL-C (mg/dL) | 50.9±13.9 | 52.9±14.0 | 0.373 | 51.5±13.5 | 52.3±14.8 | 0.741 | 52.6±12.3 | 50.9±15.0 | 0.426 | 54.4±13.8 | 53.0±14.7 | 0.564 |
| TG (mg/dL) | 121.4±110.2 | 95.6±50.6 | 0.085 | 114.3±95.6 | 96.1±52.6 | 0.172 | 121.0±71.9 | 116.9±109.7 | 0.811 | 111.4±63.8 | 126.1±104.1 | 0.369 |
| TC/HDL ratio | 3.5±1.1 | 3.3±1.1 | 0.382 | 3.4±1.0 | 3.4±1.0 | 0.805 | 3.4±0.9 | 3.5±1.1 | 0.476 | 3.4±0.9 | 3.5±1.0 | 0.454 |
| LDL/HDL ratio | 2.2±0.9 | 2.2±0.9 | 0.903 | 2.3±0.9 | 2.3±0.9 | 0.917 | 2.2±0.8 | 2.3±0.8 | 0.820 | 2.3±0.8 | 2.3±0.9 | 0.717 |
Values are presented as mean±standard deviation.
TAF, tenofovir alafenamide; CHB, chronic hepatitis B; HBV, hepatitis B virus; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; TG, triglyceride.